Peregrine secures new loan facility to fund ops and progress bavituximab
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals has secured a $30 million term loan from three different banks that will give the Tustin, California-based company sufficient capital to fund its operations for at least the next 12 months and advance its lead programme, the first-in-class phosphatidylserine inhibitor bavituximab, toward Phase III development.